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Abstract
Leishmania spp. is a protozoan parasite and the causative agent of leishmaniasis. Thymi-
dine kinase (TK) catalyses the transfer of the γ-phosphate of ATP to 2’-deoxythymidine
(dThd) forming thymidine monophosphate (dTMP). L.major Type II TK (LmTK) has been
previously shown to be important for infectivity of the parasite and therefore has potential as
a drug target for anti-leishmanial therapy. In this study, we determined the enzymatic prop-
erties and the 3D structures of holo forms of the enzyme. LmTK efficiently phosphorylates
dThd and dUrd and has high structural homology to TKs from other species. However, it sig-
nificantly differs in its kinetic properties from Trypanosoma brucei TK since purines are not
substrates of the enzyme and dNTPs such as dUTP inhibit LmTK. The enzyme had Km and
kcat values for dThd of 1.1 μM and 2.62 s
-1 and exhibits cooperative binding for ATP. Addi-
tionally, we show that the anti-retroviral prodrug zidovudine (3-azido-3-deoxythymidine,
AZT) and 5’-modified dUrd can be readily phosphorylated by LmTK. The production of re-
combinant enzyme at a level suitable for structural studies was achieved by the construction
of C-terminal truncated versions of the enzyme and the use of a baculoviral expression sys-
tem. The structures of the catalytic core of LmTK in complex with dThd, the negative feed-
back regulator dTTP and the bi-substrate analogue AP5dT, were determined to 2.74, 3.00
and 2.40 Å, respectively, and provide the structural basis for exclusion of purines and dNTP
inhibition. The results will aid the process of rational drug design with LmTK as a potential
target for anti-leishmanial drugs.
Author Summary
The DNA within the genome of an organism encodes all the information, firstly for repro-
duction and secondly for translation into proteins—the workhorses of a biological cell.
Proteins carry out a host of essential biological activities within the cell. A full understand-
ing of a protein now requires determination of a wide range of its properties in solution in
the cell and in vitro in solution, but in addition, its 3D structure usually determined by X-
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ray crystallography. Leishmania species are a family of protozoan parasites of humans and
the causative agent of leishmaniasis, a major health concern in the developing world. Se-
lective inhibition of key enzymes in these parasites is a key route for combating these dis-
eases. We have focused our work on thymidine kinase, an important enzyme from
Leishmania major, and a potential target for the development of new drugs. We have car-
ried out kinetic studies of the enzyme’s activity in solution and determined its 3D crystal
structure, enabling rational drug design.
Introduction
Leishmania spp. are flagellate protozoan parasites of the order Kinetoplastida, transmitted by
the bite of sand flies of the genera Phlebotomus and Lutzomyia [1]. They are the causative
agents for a range of forms of leishmaniases, disease with approximately 1.3 million new cases
and 20 000–30 000 deaths occurring annually [2]. Current treatments cause severe adverse ef-
fects, their efficiency is limited and the high costs make reliable supply in poor countries diffi-
cult, reviewed in [3]. Therefore, there is an urgent need for novel, less toxic and cost-effective
anti-leishmanial compounds.
Nucleotide metabolism provides a rich source of drug targets for many diseases since a bal-
anced pool of deoxyribonucleotides (dNTPs) is essential for DNA replication and repair and
disturbances in the supply of the four dNTPs may lead to genetic mutations and eventually to
cell death. In most living organisms dNTPs can be supplied by two pathways, the de novo and
the salvage pathway [4]. Leishmania parasites have both pyrimidine biosynthetic de novo and
salvage pathways but are incapable of synthesising purines de novo [5].
Thymidine kinases (TKs, EC 2.7.1.21) are essential enzymes for the initiation of the pyrimi-
dine salvage pathway as they catalyse the magnesium dependent transfer of the γ-phosphate of
ATP to thymidine (dThd), thus forming thymidine monophosphate (dTMP). dTMP is phos-
phorylated further by cellular enzymes to 2'-deoxythymidine triphosphate (dTTP), which
serves as a substrate for DNA polymerase during replication [6]. Hence TKs control the dTTP
pool and are important regulatory enzymes for DNA biosynthesis. Severe dTTP depletion
leads to the massive incorporation of uracil into DNA and contributes to the phenomenon
called “thymineless death” [4]. TKs are classified into two subgroups (types I and II) according
to their sequence and substrate specificity. Type I TKs include herpes simplex virus TK
(HSV-TK) and mitochondrial human TK2. The much more widely spread type II TKs are
present in most organisms: eukaryotes (for example protozoan parasites like Leishmania spp.
and Cryptosporidium spp.; plants; and cytosolic human TK1), bacteria (including Escherichia
coli, Ureaplasma urealyticum, Bacillus anthracis,Mycoplasma pneumoniae) and many viruses
such as variola, vaccinia and poxviridae [7–14].
Human TK1 (hTK1) is the most studied type II enzyme highlighting key features of this
subfamily of kinases. Its expression is tightly regulated throughout the cell cycle due to specific
S-phase regulated expression, reaching maximum levels in proliferating tissues, and increased
TK activity in cancer cells can be used as a tumour marker [15–17]. Alterations in TK knock
out mice indicate that the pyrimidine nucleotide salvage pathway is indispensable in vivo [18].
Type II TKs are highly specific towards nucleotide substrate accepting only thymidine or uracil
as base, or analogues with minor changes in the 5-position of the pyrimidine base and/or in the
3’-position of 2’-deoxyribose sugars [19].
The enzymes from Leishmania spp. are type II TKs with a ~100 amino acid C-terminal ex-
tension compared to those from other species. The function of this extension is not known.
Thymidine Kinase from Leishmania major
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003781 May 15, 2015 2 / 19
Diamond: http://www.diamond.ac.uk/Home.html
Trypobase: http://ec.europa.eu/research/health/
infectious-diseases/neglected-diseases/projects/008_
en.html Junta: http://www.juntadeandalucia.es/
servicios/ayudas/detalle/70293.html Plan: http://www.
idi.mineco.gob.es/portal/site/MICINN/menuitem.
7eeac5cd345b4f34f09dfd1001432ea0/?vgnextoid=
83b192b9036c2210VgnVCM1000001d04140aRCRD
Ricet FIS: For the Ricet http://www.isciii.es/ISCIII/es/
contenidos/fd-investigacion/fd-ejecucion/fd-centros-
participados/centros-participados-redes-retics.shtml.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Leishmania donovani TK (LdTK) has been shown to be located in the cytosol. L.major TK
(LmTK) knockout mutants show morphological defects, lower proliferation rates and are less
infective [13]. Since TK activity is important for Leishmania spp., the aim of the present study
was the purification and structural and kinetic characterization of recombinant type II LmTK
to identify differences from the human enzyme which might be exploited in drug design.
Materials and Methods
Bacterial strains, plasmids and chemical reagents
The pET28a and pET22b expression system, E. coli BL21(DE3), XL-1Blue strains and benzo-
nase were purchased from Novagen. The pGEMT vector, Wizard Plus SV Minipreps DNA Pu-
rification System and FuGene1HD transfection reagent were from Promega. The In-Fusion™
enzyme was purchased from Clontech-Takara Bio Europe. L-lactate dehydrogenase from rab-
bit muscle, restriction enzymes and protease inhibitor cocktail were supplied by Roche. All nu-
cleosides and nucleotides were purchased from Sigma-Aldrich and Jena Bioscience.
Cloning of the LmTK gene for expression in E. coli
The LmTK gene (GeneDB LmjF.21.1210) was amplified using the PCR Extender System, from
genomic DNA of L.major strain Friedlin with oligonucleotide primers 5´-CAT ATG TTC
CGC GGT CGT ATA GAG-3´ and 5´-CTC GAG TCA CTC TGA GGA TGC AGC-3´ that in-
clude NdeI and XhoI restriction sites (in bold), respectively. The amplified full-length LmTK
was cloned into the pGEMT vector and subsequently ligated into the NdeI and XhoI sites of
pET28a vector. The resulting construct contained a His-tag at the N-terminus. Additionally
LmTK was cloned into the expression vector pET22b, which carries a C-terminal His-tag se-
quence using the restriction sites of NdeI andHindIII. Plasmid DNA was isolated with the Wiz-
ard Plus SV Minipreps DNA Purification System (Promega). Positive clones were verified by
genomic digestion and double-stranded DNA sequencing.
Protein expression in E. coli and purification
Recombinant full-length LmTK was overexpressed from the pET28-LmTK vector in E. coli
BL21 (DE3) and grown in LB medium supplemented with kanamycin 50 μg/ml. Protein ex-
pression was induced with 0.5 mM IPTG for 5–6 hours and purification performed using a
1 ml HisTrap column. Cell pellets obtained by centrifugation of a 2 L induced culture were
washed with PBS, pH 7.2. The pellet was resuspended in buffer A (20 mM Tris-HCl, 10 mM
MgCl2, 0.5 M NaCl, 1 mM PMSF and 20 mM imidazole, at pH 7.4) supplemented with a prote-
ase inhibitor cocktail. Bacterial cells were then lysed by discontinuous sonication. The cell ex-
tract was cleared by centrifugation at 11 000 x g for 30 min at 4°C and the supernatant loaded
onto an equilibrated 1 mL HisTrap column connected to an AKTA purifier (GE Healthcare).
The column was washed with 10 mL of lysis buffer and the protein eluted using an imidazole
gradient from 20 mM to 1 M, at a flow rate of 0.5 ml/min.
Fractions containing LmTK were pooled and desalted using a PD-10 column. The enzyme
was eluted with 20 mM Tris-HCl pH 8.0, 10 mMMgCl2, 0.15 M NaCl and concentrated by
centrifugation in 10 KDa Centriprep centrifugal devices. The yield of purified protein was
4–6 mg/L. Purified LmTK was stored at -80°C after addition of 1 mMDTT and 50% (v/v) glyc-
erol. Protein identification by peptide mapping fingerprinting and molecular mass determina-
tion were performed at the Proteomics Unit of the Institute of Parasitology and Biomedicine
López-Neyra using a Voyager DE-PROMALDI-TOF spectrometer (Applied Biosystems,
USA). This material was sufficient for kinetic analyses.
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For structural studies, a total of 26 full-length and truncated LmTK constructs were tested
for expression using various E. coli strains, different media, induction systems and tempera-
tures. Additionally more than 30 different cell lysis conditions and various buffer systems were
tried for stabilisation of the protein. However, none gave sufficient amounts of soluble and sta-
ble protein for crystallization screening as it lost enzymatic activity and precipitated within
24 h at room temperature and 4°C. Therefore, expression in insect cells using the baculovirus
system was used, see below.
Activity assay
TK activity was measured spectrophotometrically using an enzyme coupled assay [20] in buffer
containing 50 mM Tris-HCl pH 7.4, 5 mMMgCl2, 50 mM KCl, 1 mMDTT, 0.5 mM ATP,
0.5 mM phosphoenolpyruvate (PEP), 0.2 mM NADH, 0.2 mM thymidine (dThd), 2 U pyru-
vate kinase (PK), 4 U lactate dehydrogenase (LDH) and variable amounts of enzyme. The reac-
tion rate (AU/min) was registered as a decrease in absorbance at 340nm (NADH extinction
coefficient) at 25°C at pH 7.4 using a multicell Hewlett-Packard 8452 diode array UV-VIS
spectrophotometer. Diluted stocks of frozen full-length LmTK were freshly prepared in assay
buffer before the measurements.
Nucleotide analysis by HPLC
Complementary activity measurements were carried out using a direct method based on the
HPLC separation of nucleotide substrates and products and their UV-visible detection at
254 nm using an AKTA purifier [21]. The number of phosphate groups determines their differ-
ent times in a MonoQ 5/50 GL column (GE Healthcare). The reaction was performed in 100 μl
of buffer containing 50 mM Tris-HCl pH 7.2, 40 mMKCl, 2 mMMgCl2, 0.5 mMDTT with
11 μg of enzyme and 50 nmol of dThd and ATP. The reaction mixture was incubated for 10 min-
utes at 25°C before being loaded onto the column. Reaction products were eluted in NaH2PO4
pH 7, at a flow rate of 0.3 mlmin-1 with a salt gradient of 50 to 350 mMNaCl. Standard solu-
tions of dThd, ATP, ADP and dTMP were injected and eluted under the same conditions to de-
termine their retention times.
Inhibition assay
The method consists in determining experimental values for the initial velocities, v, as de-
scribed above, at increasing inhibitor concentrations, added before initiating the reaction.
LmTK and dThd concentrations were 22.3 nM and 25 μM respectively. The concentration of
inhibitor that inhibits the activity by 50% (IC50) was calculated.
Construction of baculoviruses
Recombinant full length and a C-terminal truncated version of LmTK spanning amino acids
2–185, were expressed in insect cells using the baculovirus system. Transfer vectors were con-
structed by ligation-independent cloning [22] using In-Fusion™ enzyme (Clontech-Takara Bio
Europe) and incorporated either a N-terminal His6 tag, cleavable by rhinovirus 3C protease, or
a C-terminal His6 tag. Baculoviruses were constructed as follows. Sf9 cells were grown in Sf900
II-SFM media and plated in 24-well plates to a density of ~ 5 x 105 cellsmL-1 at 500 μL per
well. Attachment to the well surface was allowed in 1 h incubation at room temperature prior
to co-transfection. For transfection 4 μL (100 -500 ng depending on construct) of pOPIN trans-
fer vector, 2.5 μL (500 ng) linearised Autographa californica bacmid [23], 0.75 μL FuGene1
HD (Promega) and 50 μL Sf900 II-SFM were mixed and pre-incubated for 30 min at room
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temperature before addition to the adherent Sf9 cells. The primary viral stocks were harvested
manually from the media 168 h post-transfection. These virus stocks were used for infection of
fresh Sf9 cells, which were grown to a density of ~1 x 106 cellsmL-1, plated in 24-well plates
with 500 μL per well and allowed to attach to the well surface 1 h prior to the infection. Adher-
ent cells were infected with 5 μL primary virus stock. Final virus stocks were harvested manual-
ly from the supernatant 168 h post-infection and stored at -80°C.
Protein expression in Sf9 insect cells and purification
A small-scale expression test was set up using 5 mL Sf9 cultures and two viral concentrations
(5 μL or 50 μL of virus per 5 mL of culture) and two harvest points (48 and 72 hours). Soluble
expression was determined using a small-scale Ni-NTA purification followed by SDS-PAGE
analysis [22]. The optimal virus volume/cell and time of harvest determined in the small-scale
expression screen were used for scaling up protein expression. Thus 1 L cultures at 1 x 106
cellsmL-1 were infected with 500 μl of amplified virus and incubated at 26°C for 72 hours.
Cells were harvested by centrifugation for 30 min at 5000 x g.
Cell pellets from each 1 L culture were resuspended in 35 mL lysis buffer (20 mM Tris pH
8.0, 300 mMNaCl, 30 mM imidazole, 1 mM DTT and 100 μM PMSF) and lysed by sonication.
This was followed by addition of 25–29 U benzonase to degrade nucleic acids, incubating for
10 min at room temperature. The cell debris was removed by centrifugation for 30 min at
5000 x g and 4°C and the supernatant loaded onto an equilibrated 1 mL HisTrap crude FF col-
umn for 1 h in a loop on ice. After washing with 10 mL lysis buffer the column was connected
to an AKTA purifier, washed with another 10 mL of lysis buffer and eluted with an imidazole
gradient from 30 mM to 500 mM. The protein containing fractions were pooled and concen-
trated up to 4 mL total volume. In order to stabilise the protein, it was diluted with 1 mL Size
Exclusion Chromatography (SEC) buffer (10 mM Tris pH 8.0, 200 mMNaCl, 1 mMDTT)
containing 1 μMZnSO4.
The construct with a non-cleavable C-terminal His-tag was concentrated further to 250 μL
total volume. Size exclusion chromatography on an equilibrated Superdex 200 column was car-
ried out in SEC buffer (as above). Protein-containing fractions were pooled and in order to pre-
vent protein precipitation and degradation, it proved necessary to stabilise the solution by
addition of either 1 mM dThd, 1 mM AppNHp and 3 mMMgCl2 or 1 mM dTTP and 3 mM
MgCl2. The first condition was aimed at crystallising a complex with dThd and AppNHp, the
second at a complex with dTTP. The stabilised protein was concentrated to 2.4 mgmL-1
(dThd, AppNHp, MgCl2) and 7.3 mgmL-1 (dTTP, MgCl2), aliquoted, flash frozen in liquid ni-
trogen and stored at -80°C.
LmTK with a cleavable N-terminal His-tag was diluted with SEC 1:2. To remove the His-tag
HRV 3C protease was added in a ratio of 1:100 (protease:LmTK) and incubated at 4°C over-
night. Proteolysis was monitored by SDS-PAGE and reached ~90% after 16 h. The protein
buffer was exchanged into lysis buffer using Centrifuge filters (Amicon1 Ultra Centrifugal Fil-
ter fromMillipore, 30 kDa cutoff) and nickel affinity purification performed as above. The tag-
free LmTK in the flowthrough was concentrated to 250 μL total volume and injected onto an
equilibrated Superdex 200 column and the final purity analysed by SDS-PAGE. Protein-con-
taining fractions were pooled and concentrated to 15.1 mgmL-1 in the presence of 1 mM
dThd,1 mM AppNHp and 3 mMMgCl2. Concentrated protein was aliquoted, flash frozen in
liquid nitrogen and stored at -80°C.
Prior to crystallization the polydispersity was determined by dynamic light scattering (DLS)
at 20°Cusing a DynaPro™ (Protein Solutions™). The protein was diluted in SEC buffer to a total
concentration of 3 mgmL-1 with a total sample volume of 20 μL.
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Analytical ultracentrifugation of LmTK
C-terminal histagged LmTK stabilized with dTTP was dialyzed against SEC buffer to remove
dTTP and subsequently diluted with dialysis buffer to 0.15 mgmL-1 and 0.45 mgmL-1. C-ter-
minal histagged LmTK stabilized with dThd and AppNHp was dialyzed against SEC buffer
containing 1 mM dThd and 1 mM AppNHp and diluted in dialysis buffer to 0.15 mgmL-1 and
1.0 mgmL-1. Analytical ultracentrifugation on all samples was carried out with a Beckman Op-
tima XL/1 (Beckman Coulter) using an AN50Ti rotor at 42 000 rpm and 20°C. Sedimentation
was recorded using the refractive index with the respective dialysis buffers as reference.
Crystallization, data collection and structure solution
Commercial screens (Index, PACT and JCSG) were set up in sitting-drop vapour diffusion for-
mat with 150 nL protein solution including additives plus an equal volume of precipitant using
a Mosquito robot (TTP Labtech, UK). Crystals were optimised with 1 μL protein solution plus
an equal volume of precipitant. The crystal used to solve the structure in complex with dThd
and phosphate (LmTK-dThd), was grown in 1.4 M Na/K PO4 pH 5.4, 1 mM dThd, 1 mM
AppNHp and 3 mMMgCl2 and had a hexagonal rod shape with approximate dimensions
300x100x100 μm3. The crystal of the LmTK-dTTP complex was grown from 50 mMHEPES
pH 8.0 and 36% (w/v) penta-erythritol-propoxylate with 1 mM dTTP and 3 mMMgCl2 added
to the protein, and had an irregular shape reaching a maximum size of ~30 x 30 x 60 μm3. The
crystal leading to the complex with P1-(5-adenosyl)-P5-(5-thymidyl) pentaphosphate
(LmTK-AP5dT) showed a needle-like morphology of ~50 μm length and grew in 0.1 M tri-so-
dium citrate pH 5.5 and 20% (w/v) PEG 3000 with addition of 1 mM AP5dT to protein already
containing 1 mM dThd, 1 mM AppNHp and 3 mMMgCl2. The crystals were not cryo-pro-
tected before vitrification.
Diffraction data of all three crystals were collected at the Diamond Light Source (DLS). All
computations were carried out using the CCP4 software package [24]. The images were pro-
cessed with MOSFLM [25] and AIMLESS [26]. Details of data collection, crystallographic data
and statistics are summarised in Table 1.
The structures were solved by molecular replacement using PHASER [27] using the struc-
ture of T. brucei TK (TbTK) (manuscript in preparation) with 58% sequence identity as search
model. The LmTK-dThd and LmTK-AP5dT structures had two protomers (half a tetramer) in
the asymmetric unit, whilst the LmTK-dTTP complex had two tetramers in the asymmetric
unit. Refinement was performed using REFMAC5 [28] with one TLS group per chain and local
NCS restraints automatically generated by REFMAC5. For the first few rounds external re-
straints generated from TbTK using ProSMART [29] were applied. The last rounds of refine-
ment were carried out with the jelly body option with sigma 0.02. Model building and fitting of
the ligands were carried out in COOT [30] and the models were validated in COOT andMol-
Probity [31].
Results and Discussion
Expression and purification
Full-length LmTK was expressed in E. coli with N-terminal and C-terminal His-tag fusions.
Both were catalytically active and the N-terminal His-tagged LmTK was successfully purified
using metal affinity chromatography. The enzyme was stable at—80°C for several weeks and
enzyme purity was assessed by SDS-PAGE that gave a single band with minor contaminants
that accounted for less than 3% of the total protein. The identity of the protein was confirmed
by tryptic digestion and peptide fingerprinting and the minor contaminants were identified as
Thymidine Kinase from Leishmania major
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Table 1. Crystallographic data and statistics.
LmTK-dThd-AppNHp LmTK-dTTP LmTK-AP5dT
Data collection
Diffraction Source DLS beamline I04 DLS beamline I04 DLS beamline I24
Wavelength (Å) 0.9795 0.9795 0.9686
Temperature (K) 100 100 100
Detector Pilatus 6M-F Pilatus 6M-F Pilatus3 6M
Rotation range per image (°) 0.2 0.2 0.1
Total Rotation range (°) 72 80 90
Crystal data
Space group P6522 P1 P6522
a, b, c (Å) 121.1, 121.1, 116.2 61.60, 61.63, 110.1 64.15, 64.15, 324.6
α, β, γ (°) 90, 90, 120 81.07, 85.8, 74.94 90, 90, 120
Resolution (Å) 52.46–2.74 (2.88–2.74) 59.45–3.00 (3.16–3.00) 45.84–2.40 (2.49–2.40)
Total Reﬂections 271650 (35991) 58503 (8708) 137341 (12676)
Unique Reﬂections 13223 (1772) 29290 (4271) 16728 (1684)
Completeness (%) 96.3 (100) 94.7 (94.7) 99.9 (99.6)
Redundancy 20.5 (20.3) 2.0 (2.0) 8.2 (7.5)
Rmerge 0.110 (1.174) 0.135 (0.600) 0.118 (0.690)
Mean [I/σ (I)] 17.3 (2.9) 6.2 (2.1) 11.0 (2.7)
Matthews’ coefﬁcient (Å3/Da) 2.93 2.26 2.19
Protomers per AU 2 8 2
Reﬁnement statistics
Reﬂections, working set 12506 27884 15762
Reﬂections, test set 648 1404 829
Resolution Range (Å) 52.46–2.74 59.45–3.00 45.84–2.40
R-factor 0.2822 0.2603 0.1955
Rfree 0.3104 0.2784 0.2569
No. of non-H atoms
Protein 2370 9673 2598
Ligand 49 232 112
Water 13 53 57
Mean B factors (Å2)
Protein 88.8 49.5 29.8
Ligands 71.7 38.1 51.6
Water 57.1 22.8 40.4
RMS deviation from ideal
Bond length (Å) 0.0065 0.0094 0.0124
Bond angles (°) 1.2916 1.4449 1.6943
Ramachandran Plot1 (%)
Residues in favored region 94.94 96.00 95.43
Residues in allowed region 5.06 4.00 4.57
Outliers 0 0 0
Molprobity score 1.67 1.69 1.07
Poor Rotamers2 (%) 0 0.11 0.75
PDB ID 4uxi 4uxj 4uxh
1 Ramachandran Plot generated with COOT (Emsley et al., 2010).
2 Poor Rotamer analysis performed using Molprobity (Chen et al., 2010).
doi:10.1371/journal.pntd.0003781.t001
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mostly degradation products of LmTK. The molecular mass of the major component was
33602 ± 5 Da in agreement with that calculated for the His-tagged LmTK missing the initial
methionine residue (33733.5 Da), with a second significant peak at 33781 Da possibly caused
by an oxidized cysteine residue. Kinetic measurements and characterization of the enzyme
were carried out using this preparation.
Although the yield and stability of full-length LmTK produced in E. coli was adequate for ki-
netic measurements, it was not sufficient for structural studies. Therefore, protein expression
was switched to insect cells using the baculovirus system and a C-terminally truncated LmTK,
spanning amino acids 2–185, was successfully produced for crystallization trials. The truncated
version was designed based on homology to other TKs (alignment in S1 Fig) to exclude disor-
dered regions (S2 Fig) with a very high theoretical pI predicted using both RONN [32] and
XtalPred-RF [33,34]. Versions with either a cleavable N-terminal His tag or a C-terminal His
tag were constructed and both gave similar yields of protein (~ 3 mg per L culture). The His-
tag was cleaved from the N-His construct by digestion with 3 C proteases to yield untagged
LmTK. To prevent precipitation during purification either dThd and AppNHp or dTTP were
added. Protein purity was monitored by SDS-PAGE and no degradation could be detected.
DLS analysis showed the C-terminal His-tagged truncated LmTK to be monodisperse while
the untagged protein displayed a polydispersity of 45.3%. Despite the polydispersity of the lat-
ter sample, both protein preparations were successfully used for crystallization screening.
Substrate specificity
The specific activity under the standard assay conditions at saturating concentrations of dThd
and ATP was 4.5 μmolmin-1mg-1, similar to that reported for T. brucei TK (TbTK) [35]. The
activity was examined in the pH range 5–10 and showed an optimum at pH 8.0 (S3 Fig), thus
within the range for maximum cytosolic hTK1 activity [36,37]. The nature of the reaction
products was confirmed using HPLC.
LmTK displays positive cooperativity for ATP (Hill coefficient 1.6) with a K0.5 of
58.6 ± 2.4 μM at saturating dThd concentrations (Fig 1A). This behaviour is consistent with
the reported modulation of some TK1-like enzyme activities upon ATP binding, mediated by
the catalytic residues of the P-loop, which are highly conserved [36,38–42]. LmTK efficiently
phosphorylates its natural substrates (dThd and dUrd), with the KM for dU being approxi-
mately 10-fold higher than that for dThd (Table 2). The KM for dThd was 1.1 μM, ~ 7-fold
lower than that reported for TbTK [35]. The recombinant enzyme phosphorylates Urd but to a
much lower extent (KM = 1462 μM). In contrast, purines and pyrimidines are only very poor
substrates. Thus, at 10 mM, the rate of phosphorylation of dIno, dGuo and dAdo, by LmTKwas
23, 10 and 6 fold lower respectively than the Vmax value exhibited by TbTK for these sub-
strates. Kinetic parameters for the substrates dUrd, 5F-2’dU and AZT were similar to those
previously reported for the human enzyme (Table 2, [43]).
In addition, various sugar and base modified dUrd and dThd analogues were tested
(Table 2). Deoxyuridine analogues with halogens at position 5 were good substrates exhibiting
KM for 5F-2’dU and 5Br-2’dU of 5.7 and 2.0 μM respectively and kcat/KM values higher than
those for dU. 5CH2OH-2’dU is also phosphorylated while 5F-5’dU is not. The enzyme can also
activate ziduvudine (3’-azido-3’-deoxythymidine, AZT), with a KM of 3.0 μM.
Enzyme inhibition
TK activity is strictly regulated to maintain the nucleotide pool. The end product of the thymi-
dine salvage pathway, dTTP, exerts strong feedback inhibition, limiting the phosphorylation of
lethal nucleoside analogues or DNA chain terminators both in mam006Dalian and in T. brucei
Thymidine Kinase from Leishmania major
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003781 May 15, 2015 8 / 19
TKs [35,44–48]. The inhibition by dTTP was first measured with LmTK at saturating ATP lev-
els (0.5 mM) and equimolar concentrations of dTTP and dThd (0.2 mM) resulting in 98% en-
zyme inhibition. Comparable results were obtained for partially purified TK from rat liver
(87% inhibition) under similar conditions [44]. The determination of the IC50 value for dTTP
was performed at increasing dTTP concentrations using saturating concentrations of ATP
(0.5 mM) and dThd (25 μM) and gave a value of 3.8 ± 0.07 μM and a positive Hill coefficient
(h = 1.6) (Fig 1B). On the other hand, an analysis of the inhibition of 3.5 μM dTTP at variable
ATP concentrations (50–500 μM) and 25 μM dThd showed a 5-fold increase in the K0.5 value
for ATP compared to that in the absence of dTTP (Fig 1C). It is important to emphasize that
Fig 1. Kinetic analysis of LmTK. (A) ATP substrate dependent specific activity. Experiments were performed at 25 μM dThd and kinetic constants obtained
by a least-squares best fit of the experimental data to the Hill equation. (B) Inhibition of enzyme activity by dTTP. Experiments were performed at 25 μM dThd
and 500 μMATP. The IC50 value was calculated by non-linear regression analysis of the data. (C) The modulating effect of ATP on the inhibition of LmTK by
dTTP. dTMP formation was monitored at variable ATP concentrations and 25 μM dThd; in the absence of dTTP and in the presence of 3.5 μM and 7 μM
dTTP. (D) Inhibition of enzyme activity by AP5dT. Experiments were performed at 25 μM dThd and 500 μMATP. The IC50 value was calculated by non-linear
regression analysis. Each point represents the average of three determinations, and error bars represent the standard deviation.
doi:10.1371/journal.pntd.0003781.g001
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all dTTP experiments were performed at pH 7.4 as it has been reported that small fluctuations
around this value modulate the feedback inhibition since dTTP has a pKa2 of 7.5 [48].
Potential inhibition by other nucleotides was monitored. It has previously been described
that other dNTPs have no effect on TbTK activity [35,44]. Here we found that dUTP and to a
much lower extent dGTP and dCTP, inhibit LmTK with IC50 values of 187 μM, 549 μM and
1252 μM respectively. dTMP also inhibits the activity with an IC50 of 165 μM. The purine nu-
cleoside adenosine shows no inhibition when tested at 5 mM.
Bisubstrate analogues, with thymidine and adenosine linked by a phosphoryl chain
(ApndT), have been identified as potent inhibitors of hTK1 and TMPK. Ap5dT proved to be
the most active with a Ki of 0.12 μM for both enzymes [49]. Ap5dT was also a strong inhibitor
of LmTK with an IC50 value of 1.1 μM (Fig 1D).
Crystal structures
LmTK significantly differs in its primary sequence from TbTK since the latter is a tandem pro-
tein composed of two TK domains [35] while the L.major enzyme contains a single TK do-
main. The LmTK constructs forming diffracting crystals were heavily truncated, lacking the
largely disordered C-terminal extension of unknown function. No screens were performed
with the apo-enzyme as it was necessary to add ligands to achieve stable and soluble protein.
LmTK was crystallised with the substrate dThd plus the non-hydrolysable ATP-analogue
Table 2. Kinetic constants and substrate specificity of recombinant LmTK and hTK1.
Substrate KM Vmax kcat kcat/KM
(μM) (μmolmin-1mg-1) (s-1) (s-1.M-1)
LmTK
dThd 1.10 ± 0.33 4.66 ± 0.63 2.62 2.38 x 106
dUrd 11.1 ± 2.7 5.45 ± 0.77 3.06 2.76 x 105
dCyd N.D. 0.07a N.D.
dAdo N.D. 0.01a N.D.
dGuo N.D. 0.04a N.D.
Urd 1462 ± 158 0.79 ± 0.12 0.44 3.03 x 102
Cyd N.D. 0.00a N.D.
Ado N.D. 0.00a N.D.
Guo N.D. 0.00a N.D.
dIno N.D. 0.04a N.D.
AZT 3.04 ± 0.76 3.52 ± 0.56 1.97 6.51 x 105
5F-2’dU 5.72 ± 0.56 8.29 ± 1.12 4.66 8.14 x 105
5Br-2’dU 2.05 ± 0.33 6.17 ± 0.19 3.47 1.69 x 106
5CH2OH-2’dU 96.7 ± 23.1 5.01 ± 1.30 2.82 2.91 x 10
4
5F-5’dU N.D. 0.00a N.D.
hTK1b
dUrd 9.0 11.87 5.07 0.56 x 106
AZT 0.6 4.96 2.12 3.53 x 106
5F-2’dU 2.2 8.99 3.84 1.74 x 106
Kinetic parameters for LmTK are means of two or more independent experiments.
N.D. Not determined.
a Activity measurements at 10 mM substrate concentration.
b Kinetic constants obtained at 37°C by Munch-Peterson et al. [43].
doi:10.1371/journal.pntd.0003781.t002
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AppNHp as the phosphate donor, and in the presence of the inhibitors dTTP and AP5dT.
Seeding experiments failed to improve the crystal quality for the dThd-AppNHp or
dTTP crystals.
In all three structures analysis with PISA [50] suggest the tetramer as the most likely biologi-
cal entity, in keeping with all structures of type II TKs in the PDB. The overall structure of the
LmTK catalytic domain in all three complexes shows a nearly identical fold to those of type II
TKs from other species, as expected from the sequence identity of ~50% on the amino acid
level. The structure superposes with hTK1 (PDB: 1w4r, [51] [Welin, 2004 #14] with an overall
RMSD of 0.32 Å. Each chain shows the typical two-domain structure with the active site sitting
between the domains (Fig 2A, [51] [Welin, 2004 #14]. In brief, the big N-terminal α/β-domain
consists of a central six-stranded parallel β-sheet (β1, β2, β3, β4, β5, β8), flanked by a long α-
helix (α1) and a loop region of 15–20 amino acids on one side and two shorter α-helices (α2
and α3) and a loop on the other. The conserved P-loop, responsible for phosphate binding and
essential for the kinase activity, is located between β1 and α1.
The loop region corresponding to residues 42–59 in LmTK is disordered in most TK struc-
tures in the PDB, only taking up an ordered conformation in a few chains of UuTK (2b8t, [52],
BcTK (2ja1, [53], hTK1 (1w4r, [36] and CaTK (1xx6) (Fig 2B). In most chains of the LmTK
structures this loop is also disordered. While in LmTK-dTTP it can be traced in two out of the
eight chains, this is an artefact of crystallization as it forms an additional β-strand to the central
β-sheet of a symmetry-related tetramer in the crystal lattice. Additionally, chain A of
LmTK-AP5dT shows a partial folding of this loop over the adenosine moiety, but the adenosine
is bound in a different position to that expected from comparison with other TK structures
(CaTK-ADP: 1xx6, TmTK-dThd-AppNHp: 2qq0, TmTK-Ap4dT: 2orw, BcTK-dTTP: 2ja1).
The smaller C-terminal domain contains three β-strands (β9–11) and a short α-helix (α4)
at the C-terminus. A structural Zn2+ ion is tetrahedrally coordinated by four cysteines, C140
and C143 in the loop between β9 and β10 and C173 and C176 at the start of α4. The long loop
between β10 and β11 forms a lasso structure covering the thymidine binding site, held in place
by residues R153 and Y169, stabilising the conformation of the main chain through hydrogen
bonds. Y169 is conserved in all TK sequences, R153 is changed to lysine in the Thermotoga
maritima enzyme.
Substrate and inhibitor binding
A number of published TK structures had revealed the binding sites for thymidine in a deeply
buried pocket [51,53]. In contrast there was no ordered adenine in most of the TK complexes
prepared with the aim of identifying the phosphate donor (usually ATP) site, with two excep-
tions. The structures of CaTK with ADP (1xx6) and TmTK with dThd and AppNHp (2qq0)
and Ap4dT (2orw) had adenosine bound in an equivalent position with the ATP in an exposed
site on the protein surface. In addition, there are structures of complexes of bi-substrate mimics
with extended phosphate linkers, but in these the presence of the additional phosphate groups
clearly mean that the polyphosphate chain must follow a different path from that in the real
substrate/transition state.
The structure of the LmTK-dThd complex (co-crystallised with dThd, AppNHp and mag-
nesium) contained clear electron density for dThd, but none for AppNHp or magnesium, in
both molecules in the asymmetric unit. However, there is in addition a phosphate ion bound
very close to where the β-phosphate of the AppNHp would be expected from comparison with
the structure of TmTK in complex with dThd and AppNHp (PDB ID: 2qq0). As described in
detail for hTK1 [51], the thymidine molecule is deeply buried between the two domains and is
coordinated by hydrogen bonds to the main chain (Fig 3A) while stacking and hydrophobic
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Fig 2. Structure of LmTK. (A) The protomer in complex with dThd and phosphate, ligands as spheres coloured by atom type. (B) Superposition using SSM
[55] showing the loop region corresponding to LmTK residues 42–59 of LmTK-dThd in lemon, LmTK-dTTP in green, LmTK-AP5dT in ice blue, BcTK (2ja1) in
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interactions of side chains hold the thymidine ring in place. In LmTK-dThd, the active site resi-
due E85, essential for catalysis, forms a hydrogen bond to the 5’-oxygen of the ribose ring, well
placed to act as the catalytic base, abstracting a proton from the oxygen, which is then enabled
to perform a nucleophilic attack on the γ-phosphate of the phosphate donor. The absence of
density for AppNHp, compared to the structures of CaTK and TmTK, is a result of the site
being sterically blocked in LmTK by residues of the α1-helix of the symmetry-related dimer
within the tetramer.
The LmTK–dTTP crystal has a well-resolved dTTP in the thymidine-binding site, the mag-
nesium being coordinated by the phosphates, in all eight protomers in the asymmetric unit.
The residues around the dTTP have essentially the same conformation as in the dThd complex,
with the exception of E85 that is turned away from the 5’-oxygen of the ribose ring, no longer
forming a hydrogen bond. As for the hTK1-dTTP structure (PDB ID: 1xbt), the γ-phosphate
of the dTTP lies in the position expected for the ATP β-phosphate, explaining why this ligand
acts as an inhibitor.
In the LmTK-AP5dT complex there are two chains in the AU, both with well-defined densi-
ty for the dThd moiety and the five phosphates. The coordination of dThd is essentially identi-
cal to that in the LmTK-dTTP complex, with E85 in the inactive conformation. Only chain A
exhibits good density for the adenosine, which is much less well ordered in Chain B. However,
in Chain A, the adenosine is flipped by about 180° from the position expected from the CaTK
and TmTK complexes, and lies on the surface of α/β-domain, partially covered by the poorly
ordered 42–59 loop. In LmTK-AP5dT, the phosphates have different positions from those in
the LmTK-dTTP and the TmTK-dThd-AppNHp complexes. Four of the five phosphates of the
AP5dT show identical positions to those in the hTK1-AP4dT complex (PDB: 2orv, [39]: the ad-
enine was also not visible in the latter structure. The binding site for adenine expected from the
CaTK and TmTK structures is again blocked by the adjacent dimer, just as in the LmTK-dThd
complex. Thus while the residues forming the thymidine-binding site have identical conforma-
tions in all three LmTK complexes, it is not possible to identify the adenine coordinating resi-
dues from the present structures.
Comparison of the active sites of LmTK and the human enzyme does not reveal major dif-
ferences, which is reflected in the high similarity of kinetic parameters for dUrd, 5F-2’dU and
AZT (Table 2).
Quaternary structure
All type II TK structures in the PDB are tetramers, and analysis using PISA [50] suggested the
tetramer as the likely biological entity in all the crystal forms of LmTK. The LmTK-dThd and
LmTK-AP5dT crystals contain two protomers (Fig 2C) per asymmetric unit, with the tetramer
sitting on a crystallographic 2-fold axis (Fig 2D), while the LmTK-dTTP asymmetric unit con-
tains two tetramers. That the tetramer is the stable oligomeric state in solution is confirmed by
the AUC analysis below. As discussed extensively for other TK structures, e.g. TmTK [39],
there are two protomer-protomer interfaces, the first defined by the central β-sheets of two
protomers, which come together in an anti-parallel orientation to form a continuous
12-stranded β-sheet. The second, between dimers in the tetramer, centres on the anti-parallel
interaction of the long α1-helices of the α/β-domains of two adjacent subunits.
In the absence of phosphate donor, TK structures form a closed tetramer with the long
α1-helices of the α/β-domains interacting directly. While the protomer conformation does not
orange and hTK1 (1w4r) in pale crimson. The overall fold of LmTK-dThd is shown in white. (C) The dimer in the asymmetric unit in the dThd-phosphate
complex with the ligands shown as spheres coloured by atom type. (D) The tetramer generated using PISA [56]. Figure made using CCP4mg [57].
doi:10.1371/journal.pntd.0003781.g002
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change upon phosphate donor binding, in the presence of the phosphate donor the tetramers
are more open with the α1-helices moving ~ 3 Å apart leaving space for the nucleobase. LmTK
forms closed tetramers in all three complexes, which explains the lack of density for the ade-
nine in LmTK-dThd and its unexpected position in LmTK-AP5dT.
Oligomeric state in solution
To confirm the tetramer as physiologically relevant oligomeric state, analytical ultracentrifuga-
tion was carried out on unliganded LmTK and enzyme in complex with dThd and AppNHp,
each at two different protein concentrations (Fig 4). To obtain unliganded protein, dTTP-con-
taining LmTK was dialysed extensively against ligand-free buffer, while the dialysis buffer used
for the LmTK-substrate complex contained the ligands.
At high protein concentrations, the sedimentation coefficients were 5.1 and 5.4 S for the
dThd-AppNHp complex and unliganded LmTK, respectively. SEDFIT analysis using standard
c(s) distribution model showed frictional ratios of approximately 1.3 resulting in a molecular
weight estimate of ~90 kDa, in agreement the value of 84.7 kDa expected for a tetramer, within
experimental error. The samples at lower protein concentration showed very similar sedimen-
tation coefficients rendering a concentration-dependent change of oligomeric state unlikely.
Fig 3. Stereo views of the ligand sites after superposition with SSM [55] in CCP4mg [57]. (A) The dThd binding site of hTK1 (lemon), LmTK-dThd (light
blue) and LmTK-dTTP (ice blue). (B) LmTK-dThd (dark cyan), LmTK-dTTP (ice blue), LmTK-AP5dT (light blue) and TmTK-dThd-AppNHp (tan). The P-loop of
LmTK-AP5dT is shown as a ribbon. Amino acid residues and ligands are shown as cylinders coloured by atom type with C and P atoms coloured by model.
Hydrogen bonds are shown as dashed lines.
doi:10.1371/journal.pntd.0003781.g003
Fig 4. Analytical ultracentrifugation of C-terminally His-tagged LmTK. Superposition of the c(s) distributions of the unliganded LmTK and LmTK-dThd-
AppNHp samples are shown at concentrations in the range of 1–8 S.
doi:10.1371/journal.pntd.0003781.g004
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Conclusions
While the full-length enzyme could be expressed in sufficient yield in E. coli for the kinetic
studies, only the C-terminally truncated version of LmTK, spanning amino acids 2–185, ex-
pressed soluble in sufficient amounts for structural studies, and required expression in baculo-
virus to provide stable protein in useful yield. Thus structural work was limited to the core
protein with high homology to other TK structures in the PDB. However, analysis and compar-
ison of the LmTK structures with hTK1 alongside kinetic data, allow some conclusions about
the potential use of TKs as potential targets for anti-leishmanial chemotherapeutics.
The LmTK structures form tightly packed tetramers with a blocked phosphate donor site
and are closely similar to those of other species (hTK1, [36,51]; UuTK, [52]; BaTK and BcTK,
[53]; TmTK, [38,39]; CaTK, PDB Code 1xx6). Furthermore, the tetramer was confirmed by
AUC as the oligomeric state in solution. Analysis of the active site revealed no major differ-
ences in the region coordinating the thymidine moiety. While there is a difference in the length
of the flexible loop region, missing in the structures of LmTK and hTK1, this is a crystallo-
graphic artefact. While hTK1 has the residues interacting with the ribose ring (D58) and the
transition state (R60), these residues are disordered in most of the LmTK structures hinting at
a more relaxed binding or might be a crystallographic artefact. However, it is ordered in the
structure of LmTK:AP5dT with the side chain conformations of D58 and R60 being identical to
hTK1.
Kinetic measurements of full-length LmTK showed high substrate specificity for its physio-
logical substrates dThd and dUrd. Despite the differences in substrate selectivity found between
the L.major and T. brucei TKs, a major role in the phosphorylation of Thd and dThd can be
proposed for both enzymes. Moreover, we were able to confirm dTTP and AP5dT as potent in-
hibitors of LmTK. We showed AZT and 5’-modified dUrd to be readily phosphorylated by
LmTK and this compound was shown previously to inhibit Leishmania intracellular amastigote
growth and to exhibit potential as an antiprotozoal agent [54]. However, the lack of major
structural differences in the active site of LmTK compared to the hTK1, further validated by
the similarity in their kinetic parameters for dUrd, 5F-2’dU and AZT (Table 2), might render
the design of LmTK-specific ligands challenging. Nevertheless, the data obtained for LmTK
provide a basis for the design of selective inhibitors that may have potential for the treatment
of leishmaniases.
Supporting Information
S1 Fig. Multiple sequence alignment of type II TKs. The secondary structure elements from
LmTK-dThd are displayed with α-helices as spirals and β-strands as arrows. Green bar: P-loop,
yellow triangles: zinc-coordinating cysteine residues, red stars: residues coordinating dThd via
main chain hydrogen bonds, orange stars: residues coordinating dThd via stacking or hydro-
phobic interactions of the side chains. Tc: Trypanosoma cruzi, hTK1: full-length sequence of
human TK, hTK1-1W4R: truncated hTK1 used for structure solution (PDB ID 1W4R), Vv:
Vaccinia virus, Ba: Bacillus anthracis, Uu: Ureaplasma urealyticum, Tm: Thermotoga maritima.
Alignment was carried out using M-coffee [58,59] and Espript 3.0 on http://espript.ibcp.fr
[60].
(TIFF)
S2 Fig. Disorder prediction of the LmTK sequence. Residue number plotted against probabil-
ity of disorder, calculated by RONN [32]. The green bar indicates the residue range 2–185 for
the constructs used in crystallization experiments.
(TIFF)
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S3 Fig. Effect of pH on LmTK activity. Experiments were performed at 25 μM dThd and
500 μMATP. Each point represents the average of three determinations and the error bars rep-
resent the standard deviation.
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